Explore 3 Stock Ideas & Industry Insights Download Free Report

Aktis Oncology, Inc. Common stock

Company price
16.62 USD 0.34 ( 2.09%)
Last update at 2026-11-13T21:00:00Z
VOLUME
244384
Market Cap
1246.43M

Momentum Score

…

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
15.76
Low
16.73
High
52 Week Price Range
14.72
Low
34.19
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Aktis Oncology, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ (AKTS) focused on developing oncology therapeutics; public information on its pipeline is limited. Long-term growth could be driven by positive clinical trial results, regulatory approvals and strategic partnerships that may support commercialization, offering investors exposure to potential upside from successful development in areas of unmet medical need.

Principal risks include clinical and regulatory setbacks, ongoing need for external financing, competitive pressures in oncology and limited public liquidity, which together could materially affect value.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
16.28
Dividend Yield
-
Revenue TTM
10.06M
Revenue Per Share
0.38
Gross Profit TTM
-68.22M
Debt / Equity
-0.08
ROE
-29.45%
Net Debt
-26.24M
ROCE
-31.96%
Diluted EPS TTM
-1.28

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2024-06-30 2023-12-31 2023-06-30
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2024-06-30 2023-12-31 2023-06-30
Income before tax -63.73M -43.98M -167.94M -28.64M -66.00M
Minority interest - - - - 0.19M
Net income -63.73M -43.98M -167.95M -28.64M -63.56M
Selling general administrative 12.60M 11.31M 35.88M 7.68M 29.71M
Gross profit 6.50M 1.49M -0.69M -3.12M -3.12M
Reconciled depreciation 2.33M 1.57M 13.21M 1.12M 11.65M
Ebit -74.68M -52.05M -165.29M -34.79M -63.68M
Ebitda -72.36M -50.48M -152.08M -33.60M -52.03M
Depreciation and amortization 2.33M 1.57M 13.21M 1.20M 11.65M
Non operating income net other - - - - 2.39M
Operating income -74.68M -52.05M -109.99M -34.79M -66.07M
Other operating expenses 81.18M 53.54M 137.38M 34.79M 93.19M
Interest expense - 2.66M 2.66M 2.32M 2.32M
Tax provision - - 0.01M - -2.45M
Interest income 11.01M 8.10M - 5.38M -
Net interest income 11.01M 8.10M -2.66M 5.38M -2.32M
Income tax expense - 0.01M 0.01M -2.45M -2.45M
Total revenue 6.50M 1.49M 27.38M 27.12M 27.12M
Total operating expenses 81.18M 53.54M 109.30M 34.79M 62.95M
Cost of revenue - 28.07M 28.07M 30.24M 30.24M
Total other income expense net 10.95M 8.07M -57.95M 6.15M 0.06M
Net income from continuing ops -63.73M -43.98M -167.95M -28.64M -63.56M
Net income applicable to common shares - - - - -63.56M
Breakdown 2025-12-31 2024-12-31 2024-06-30 2023-12-31 2023-06-30
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2024-06-30 2023-12-31 2023-06-30
Total assets 264.88M 326.18M 69.74M 122.36M 148.92M
Intangible assets - 12.56M 12.56M 15.24M 15.24M
Other current assets 3.52M 3.69M 4.80M 2.34M 4.44M
Total liab 411.03M 413.98M 126.83M 168.66M 62.68M
Total stockholder equity -146.15M -87.80M -57.09M -46.31M 86.24M
Deferred long term liab - - - - 43.35M
Other current liab 9.52M 6.33M 69.73M 3.75M 13.05M
Common stock - 0.12M 0.12M 0.07M 0.07M
Capital stock 0.00M 0.00M 0.12M 0.00M 0.07M
Retained earnings -156.56M -92.83M -438.51M -48.85M -270.36M
Other liab - - - - 0.12M
Good will - 6.51M 6.51M 14.56M 14.56M
Other assets - - - - 0.07M
Cash 37.78M 37.16M 24.45M 29.51M 43.10M
Total current liabilities 31.24M 18.82M 84.37M 6.24M 17.57M
Current deferred revenue 18.66M 9.28M 0.13M 0.10M 0.10M
Net debt -26.24M -25.15M 28.42M -16.11M 2.33M
Short term debt 1.31M 1.30M 10.51M 1.53M 0.44M
Short long term debt - - 10.00M - -
Short long term debt total 11.55M 12.01M 52.86M 13.40M 45.43M
Other stockholder equity 10.37M 4.91M 381.29M 2.46M 356.52M
Property plant equipment - - - - 57.83M
Total current assets 230.31M 300.85M 36.77M 100.20M 59.84M
Net tangible assets - - - - 56.44M
Short term investments 189.00M 260.01M - 68.35M -
Net receivables - 5.29M 5.29M 4.75M 4.75M
Long term debt - - 41.89M - 0.78M
Inventory - 2.22M 2.22M 7.55M 7.55M
Accounts payable 1.74M 1.92M 4.00M 0.96M 3.98M
Accumulated other comprehensive income 0.04M 0.12M - 0.08M -
Common stock total equity - - - - 0.07M
Retained earnings total equity - - - - -270.36M
Non currrent assets other 7.33M 4.46M 0.07M 1.23M 0.07M
Non current assets total 34.58M 25.33M 32.97M 22.15M 89.07M
Capital lease obligations 11.55M 12.01M 0.98M 13.40M 1.42M
Long term debt total - - - - 0.78M
Breakdown 2025-12-31 2024-12-31 2024-06-30 2023-12-31 2023-06-30
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2024-06-30 2023-12-31 2023-06-30
Investments 75.55M -187.54M -5.99M -65.12M -13.88M
Change to liabilities - - - - 4.01M
Total cashflows from investing activities 65.96M -190.40M - -68.83M -25.15M
Total cash from financing activities -1.21M 183.28M 27.68M 32.59M 32.59M
Change to operating activities - - - - -0.49M
Net income -63.73M -43.98M -167.95M -28.64M -63.56M
Change in cash 0.62M 7.65M -18.66M -98.83M -37.38M
Begin period cash flow 38.31M 30.66M 43.10M 129.49M 80.48M
End period cash flow 38.93M 38.31M 24.45M 30.66M 43.10M
Total cash from operating activities -64.13M 14.76M -40.35M -30.00M -44.82M
Issuance of capital stock 0.00M 185.00M 12.34M 0.00M 32.03M
Depreciation 2.33M 1.57M 13.21M 1.12M 11.65M
Other cashflows from investing activities - - - 0.06M 0.12M
Change to inventory - 5.33M 5.33M -3.45M -3.45M
Change to account receivables 1.03M -0.86M 0.64M -0.26M -0.08M
Sale purchase of stock - - - - 32.59M
Other cashflows from financing activities -1.55M 183.28M 7.34M 0.56M 0.56M
Change to netincome - - - - 7.20M
Capital expenditures 9.58M 2.86M 5.99M 3.76M 11.38M
Change receivables - - - - -0.08M
Cash flows other operating - - - - -0.76M
Cash and cash equivalents changes - - - - -37.38M
Change in working capital -3.23M 58.98M 65.68M -0.01M -0.68M
Stock based compensation 5.13M 2.26M 2.85M 1.48M 9.41M
Other non cash items -4.62M -4.07M 45.87M -3.95M 0.75M
Free cash flow -73.71M 11.90M -46.34M -33.77M -56.21M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
AKTS
Aktis Oncology, Inc. Common stock
0.34
2.09%
16.62 - - 123.90 2.66 77.80
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99 2.11
VRTX
Vertex Pharmaceuticals Inc
-4.02
0.74%
538.60 30.22 24.27 10.36 6.50 9.99
REGN
Regeneron Pharmaceuticals Inc
4.28
0.45%
955.47 29.07 20.12 7.57 3.82 6.95
ARGNF
argenx SE
64.70
7.19%
965.00 45.77 31.25 13.84 7.12 11.38

Profile*

Aktis Oncology, Inc. Common stock

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.

17 Drydock Avenue, Boston, MA, United States, 02210

617 461 4023

79

Name Title Year Born
Mr. Jeffrey B. Shealy Founder, Pres, CEO & Director 1969
Mr. Kenneth E. Boller CFO & Corp. Controller 1971
Mr. David M. Aichele Exec. VP of Bus. Devel. 1966
Mr. Andrew Wright Gen. Counsel & Corp. Sec. NA
Ms. Mary Winters Exec. VP of Fab & Corp. Operations NA
Mr. Kamran Cheema Chief Product Officer NA
Mr. Jeffrey B. Shealy Founder, President, CEO & Director 1969
Mr. Kenneth E. Boller CFO & Corporate Controller 1971
Mr. David M. Aichele Executive Vice President of Business Development 1966
Mr. Andrew Wright General Counsel & Corporate Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…